A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer

Anti-Cancer Drugs

Volumn 18, Issue 9, 2007, Pages 1093-1101

  Cree, Ian A ^a   Kurbacher, Christian M ^e   Lamont, Alan ^b   Hindley, Andrew C ^c   Love, Sharon ^d   Cree, I A ^f   Kurbacher, C M ^f   Lamont, A ^f   Hindley, A C ^f   Love, S ^f  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b SOUTHEND HOSPITAL   (United Kingdom)

^c ROYAL PRESTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Medical Centre Bonn   (Germany)

^f NONE

Author keywords

ATP based tumour chemosensitivity assay; Chemosensitivity; Crossover; Ovarian; Platinum; Predictive; Randomized trial; Resistance

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIFOSTINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; TREOSULFAN;

ADULT; ARTICLE; ASSAY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HAZARD RATIO; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; TUMOR CELLS, CULTURED;

EID: 34548096927     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3281de727e     Document Type: Article

References (33)

1. Ledermann JA, Wheeler S. How should we manage patients with 'platinum-sensitive' recurrent ovarian cancer? Cancer Invest 2004; 22 (Suppl 2):2-10.
2. Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 2002; 7 (Suppl 5):46-55.
3. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
4. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003; 21:2843-2848.
5. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18:1193-1202.
6. Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. Eurocare Working Group. Eur J Cancer 1998; 34 (14 Spec No):2218-2225.
7. Cree IA. Chemosensitivity testing as an aid to anti-cancer drug and regimen development. Recent Results Cancer Res 2003; 161:119-125.
8. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors:is there any alternative? Anticancer Drugs 1997; 8:541-548.
9. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, et al. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res 2003; 161:221-230.
10. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52:65-77.
11. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
12. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex-vivo chemosensitivity. Anticancer Drugs 1996; 7:630-635.
13. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RA, et al. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19:242-249.
14. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77:258-263.
15. Kurbacher CM, Cree IA, Brenne U, Bruckner HW, Kurbacher JA, Mallmann P, et al. Heterogeneity of in-vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Treat 1996; 41:161-170.
16. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, et al. Use of an ex-vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9:51-57.
17. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5:78.
18. Rustin GJ. Can we now agree to use the same definition to measure response according to CA-125? J Clin Oncol 2004; 22:4035-4036.
19. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14:1545-1551.
20. Cree IA. Luminescence-based cell viability testing. Methods Mol Biol 1998; 1998:169-177.
21. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Poch G, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3:1527-1533.
22. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005; 23:8802-8811.
23. Von Hoff DD, Kronmal R, Salmon SE, Turner J, Green JB, Bonorris JS, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991; 67:20-27.
24. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8:iii, 1-234.
25. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23:2020-2027.
26. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79:1487-1493.
27. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003; 3:19.
28. Breidenbach M, Rein DT, Mallmann P, Kurbacher CM. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anticancer Drugs 2002; 13:173-176.
29. Breidenbach M, Rein DT, Schondorf T, Schmidt T, Konig E, Valter M, Kurbacher CM. Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 2003; 14:341-346.
30. Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol 2002; 29 (1 Suppl 1):11-16.
31. Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr Opin Investig Drugs 2002; 3:634-640.
32. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005; 15 (Suppl 1):18-22.
33. Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, et al. Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs 2004; 15:861-869.